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Abstract
Background: To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish
possible effects of oral anti-hyperglycemic agents (OAAs).
Methods: A representative cohort of 800,000 subjects was obtained from the Taiwanese National Health Insurance
database on 1 January 2000. Those with consistent data (n = 762,753) were followed up between 1 January 1996
and 31 December 2007. Over this period, we assessed the presence (n = 62,988) or absence (n = 699,795) of
T2DM, and whether any OAA was used (n = 40,232) or not (n = 22,756). To compare the risk of AD by diabetic
status, those with T2DM were matched for birth date and gender with those without T2DM. To assess the effect of
OAAs, we considered those 50 years and over. Matched AD-free patients with T2DM on OAAs were compared
with those without OAAs, for age, gender, locality, health service, Charlson Comorbidity Index. and diabetes
diagnosis date to avoid immortal time bias. AD incidence densities, hazard ratios (HR) and 95% confidence intervals
(CIs) were calculated.
Results: Compared with diabetes-free subjects, the HR (95% CI) for AD was 2.62 (2.31 to 2.98) for patients with
T2DM who were not on OAAs, and 1.08 (0.99 to 1.18) for those who were on OAAs. The AD incidence density
decreased from 91.1 to 39.4 per 10,000 person-years for patients on the combination of metformin and
sulfonylurea. The HR (95% CI) for AD was 0.92 (0.59 to 1.45) for those on metformin alone, 1.08 (0.84 to 1.38) for
those on sulfonylurea alone, and 0.40 (0.32 to 0.50) for the combined treatment, and the decrease was not related
to sequence or insulin usage. Similar patterns were seen for incident AD exclusion for up to 3 years, although
more so for bipolar than unipolar.
Conclusions: The incident AD risk is increased by 2.6-fold in T2DM, and the combination of sulfonylurea and
metformin minimizes this risk.
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Background
It has been recognized that mood and behavioral disor-
ders may contribute to a co-existent clinical cluster with
diabetes [1,2]. Depression and diabetes occur together to
a greater extent than would be expected based on their
respective separate prevalences [3-9]. There has been
uncertainty about the nature of what has been regarded
as a bidirectional pathogenesis of the two conditions [10],
although a Canadian study failed to find evidence for dia-
betes being an antecedent for depression [11]. However,
studies of European and North American populations do
indicate that diabetes is a precursor of depression
[12-14]. A meta-analysis estimated that depression is a
greater precursor of diabetes than the reverse [15] and, in
a Spanish cohort, the incident diabetes rate attributable
to depression was 7% [16]. To date, most of these studies
have involved Caucasian populations, and there is little
information about the issue in those ethnicities that are
experiencing rapid and major increases in diabetes preva-
lence, such as northeast Asians. Over the period 1993 to
2008, the prevalence of diabetes in Taiwan had doubled
for men, with an increase in the age-standardized rate
from 4.6% to 9.3%, although for women, it decreased
from 7.9% to 6.4% [17]. The prevalence of major depres-
sion in Taiwan was relatively low at 1.5%, compared with
other populations; for instance it was 19.0% in Beirut
[18]. However, by 2001, prevalence of major depression
in older populations in Taiwan was 5.9% [19], compar-
able with international figures. Huang’s meta-analysis
showed that depression was 1.53 times more prevalent
among older people with chronic disease [20]. Given the
increasing diabetes prevalence, corresponding changes in
depression or affective disorder (AD) rates might be
expected if there is causality.
The question of anti-hyperglycemic management in the
prevention of depression or AD is likely to become an
increasingly relevant public-health and clinical matter.
There is increasing evidence that the therapeutic scope of
the biguanide drug metformin extends beyond its current
indications for hyperglycemia to the prevention ofpre-
viously poorly appreciated outcomes of diabetes. These
include certain cancers [21,22] and neurodegenerative
disease, notably dementia [23], and Parkinson’s disease
[24]. There may be a shared pathogenesis between dia-
betes and dementia related to oxidative stress and mito-
chondrial dysfunction, together with bioenergetics and
abnormal protein folding. Metformin may decrease any
or all of these associations. In addition, metformin has
been shown to reduce tau hyperphosphorylation, which
plays a role in the formation of the neurofibrillary tangles
in neurodegeneration [25]. It is conceivable that this
might be relevant in neuropsychiatric disorders as well,
because tauopathy is seen when depression is co-morbid
with Alzheimer’s disease [26]. In further support of this
concept, the mood-stabilizer lithium also reduces neuro-
fibrillary tangle development [27]. The extent to which
these mechanisms are relevant to the development of
depression or AD is unknown. Clarification on insulin
resistance as a risk setting for depression or AD, and the
extent to which this might be avoided, is now of consid-
erable importance as the incidence of glycemic disorders
increases globally. Moreover, diabetes and pre-diabetes
may each be underlying contributors to depression or
AD, because the glycemic disorder progresses with the
potentially reinforcing and adverse metabolic effects of
depression itself.
The lower directional effect of diabetes on depression
compared with the reverse may be due to past non-
recognition of risk reduction for depression associated
with diabetes therapy [10,12-15]. What may be of related
consequence is the potential synergy of depression and
diabetes for conventionally characterized diabetes com-
plications such as retinopathy [28]. Thus, it is possible
that some studies have not only under-recognized the
effect of type 2 diabetes (T2DM) on depression because
they have not distinguished between patients treated or
not with oral anti-hyperglycemic agents (OAAs), but
have also not recognized the mood-modifying potential
of anti-hyperglycemic agents.
In this cohort study, we followed up a representative
sample of the Taiwanese population for 12 years to
determine the effect on risk for AD of T2DM, with and
without OAA therapy, using a matching protocol to
mimic a clinical trial [24,29,30].
Methods
Ethics approval
This study was approved by the institutional review
board of the National Health Research Institutes of
Taiwan.
Data sources and study subjects
Taiwan began a national health insurance (NHI) pro-
gram in 1995. By 2007, 98.4% of Taiwan’s 22.96 million
population was enrolled in the program. Subject to a
double scrambling protocol, the NHI Research Database
is based on the registration files and original claims data
for reimbursement. The Longitudinal Health Insurance
Database 2000 contains all the original claims data of
800,000 beneficiaries, randomly sampled from the year
2000. We studied this database with antecedent data
from 1 January 1996.
We conducted two studies with different objectives:
the first to determine the effect of diabetes on AD inci-
dence, and the second to ascertain the effect of sulfony-
lureas or metformin, or a combination of both, on AD.
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Study 1
To determine the effect of diabetes on AD incidence, we
first formed a cohort of 762,753 participants with con-
sistent data, who were registered as NHI beneficiaries
on 1 January 2000 (Figure 1). They were followed up
during the period 1 January 1996 to 31 December 2007.
Assessing subjects aged 20 years or above, diabetes was
found to be present in 62,988, and absent in the remain-
ing 699,765. Of those with T2DM, 40,232 used any
OAA and 22,756 used none. People with T2DM were
matched for birth date and gender with those who were
diabetes-free, in order to compare AD incidence. Any
individual in a matched pair who had previous AD was
excluded (Figure 1A). There were 60,646 pairs success-
fully matched, of which 39,159 pairs were on OAAs and
21,487 pairs were not.
Subjects with T2DM were defined as those who had at
least two records of diabetes (ICD-9, CM-250 or A181;
(A) 
(B) 
Random sample of NHI insured in 2000, monitored from 1-1-1996 (n=800,000) 
Exclude subjects who had inconsistent data (n=37,247) 
Diabetes free in 1996-2007 (n=699,765)  20 y, Diabetes patients a (n=62,988)  
 (1) Diabetes without OAAs (n=22,756) 
 (2) Diabetes with OAAs (n=40,232) 
Matched by year and month 




No DM diagnosis Diabetes 
No DM diagnosis 
Diabetes diagnostic (index) date, 
Successfully matched-pairs (n=60,646) 
 (1) DM without OAAs (n=21,487) 
 (2) DM with OAAs (n=39,159)
Exclude subjects with affective disorders 
before index date, i.e. date of DM 
Figure 1 Patient selection and index date assignment for Study 1. (A) Flow chart of selection of patients with diabetes for comparison of
affective disorder (AD) risk with subjects who were free of both diabetes and AD. Subjects aged 20 years or over with a diagnosis of type
2 diabetes mellitus (T2DM) recorded more than once within 1 year or who had used any oral anti-hyperglycemic agent (OAA) for at least
3 months during the period 1996 to 2007 regardless of insulin usage, were evaluated. (B) Follow-up of AD onset; patients with diabetes mellitus
(DM), who did or did not use oral anti-diabetic agents (OAA). were matched with diabetes-free counterparts, who had the same index dates as
the DM diagnostic date.
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the latter was a diabetes code for ambulatory visits used
in Taiwan before 2000) within any year during the period
1996 to 2007, or had used any OAA for more than 3
months. In the same matched pair, the subject with
T2DM and the T2DM-free subject had the same diabetes
diagnostic date (index date) for follow-up (Figure 1B).
The subjects with diabetes were classified into those
using or not using OAAs during the follow-up period. We
compared the incidence of AD between three groups
(T2DM-free, T2DM on OAA, and T2DM without OAA).
An AD incident case was defined as one with at least two
records of the diagnosis of an AD (A212, or ICD-9 CM
coding 296.0 to 296.9, which covers major or unipolar
depression (296.2 and 296.3) and bipolar disorders (all
other 296.0 to 296.9, but not dysthymic disorders) within
any year during the period 1996 to 2007, but after the
diagnosis of diabetes. There were 19,009 AD cases in all:
12.073 unipolar and 6.936 bipolar.
Study 2
We further investigated the preventive effect of the
OAAs metformin and/or sulfonylureas for future AD in
subjects with T2DM. Metformin or sulfonylureas are the
most commonly used OAAs for T2DM treatment in Tai-
wan. To avoid immortal time bias [24,29,30], we matched
patients with T2DM without OAAs and those on metfor-
min or sulfonylureas by age, gender, region, level of care,
and Charlson Comorbidity Index (CCI) [31]. In the same
matched pair, the subjects with T2DM who were on met-
formin or sulfonylureas and those who were not on any
OAA had the same date (treatment initiation date) for
follow-up (Figure 2). Where necessary, a patient in the
comparison group was used more than once.
We further classified subjects with T2DM on metfor-
min or sulfonylureas into three groups: metformin only
(1,509 pairs), sulfonylureas only (2,904 pairs), and a
combination of these two drugs (5,397 pairs). The AD
incidences of the three groups were compared with the
subjects with T2DM who were not on OAAs (referent
group). An insulin user was defined as any subject who
had used it for more than 3 months; those who used
insulin briefly during hospitalization were not counted
as users.
Matching factors
Subjects’ baseline status and comorbidity were treated as
matching factors. Comorbidity was measured by the CCI
[31] using the NHI diagnoses recorded in the year
before the diagnosis of diabetes. For CCI score calcula-
tion, we did not include the diagnoses of T2DM because
this disease was considered separately in its own right.
Other factors included age (in groups aged 50 to 54, 55
to 59 60 to 64, 65 to 69, and ≥70 years), gender, locality,
and health service.
Statistical analysis
The differences between groups were evaluated by one-
way ANOVA (CCI score) or c2 test (demographics). For
the effect of diabetes on future AD, the diabetes diagnostic
date was used as the starting point to calculate survival
time (Figure 1B). For the preventive effect of metformin or
sulfonylureas on future depression in subjects with T2DM,
the treatment initiation date was used as the starting point
to calculate survival time (Figure 2B). The end of follow-
up was the onset date of AD or the date of withdrawal
from the NHI program or the end of 2007, whichever
occurred first. AD incidence density was defined as the
number of incident AD events divided by 10,000 person-
years at risk.
We used Cox proportional-hazards models to evaluate
associations between diabetes, OAAs, and AD. In addi-
tion to matching, adjustments were made for monthly
income (0, 1 to 15,000, 15,000 to 21000, and >21000 New
Taiwan Dollars (NTD)) and use of insulin (yes or no).
The statistics software SAS (version 9.1, SAS Institute,
Cary, NC, USA) was used for data management and
modeling. These models were evaluated using the pro-
gressive annual exclusion of incident AD for 3 years after
the diagnosis of diabetes. A two-sided P-value of < 0.05
was considered significant.
Results
The hazard ratio (HR) and 95% confidence interval (CI)
for AD in those with T2DM and not on OAAs were com-
pared with those who were diabetes-free, and matched for
age and gender (Figure 3). The increase in risk was 2.62-
fold (95% CI 2.31 to 2.98). For subjects with T2DM who
were on any OAA, compared with those who were dia-
betes-free, the HR of 1.06 (0.96 to 1.16) was not signifi-
cant, but it represented a normalization of that for T2DM
without OAA therapy. The analogous findings by gender
and whether AD was unipolar or bipolar are also shown.
These indicate that the effects of diabetes and of OAA are
similar for men and women and are irrespective of AD
polarity.
We calculated the prevalences of T2DM and AD for
the year 2000, and plotted them by age (Figure 4). Both
prevalences were seen to increase with age, although that
for diabetes is more striking than for AD. The steepest
increase for diabetes prevalence was between the ages of
40 and 60 years. This informed our choice of 50 years as
the age for study 2, as we considered the effects of OAA
on the incidence of AD may be more related to diabetes
in these subjects than in younger subjects. When each of
unipolar and bipolar AD prevalences were considered,
those for unipolar AD were found to increase with age,
but there was little increase for bipolar AD.
The demographics were stratified according to each
metformin or sulfonylurea category, and matched with
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those with T2DM who had had no OAA (Table 1).
There were 9,810 patients with T2DM who were on an
OAA and who could be matched with those without an
OAA for assessment of AD incidence density and risk
of AD. Neither sulfonylureas nor metformin alone were
associated with a significant change in AD incidence.
For the combination of metformin and sulfonylurea, the
incidence density decreased from 91.1 to 39.4 per
(A) 
(B) 
Random sample of NHI insured in 2000, monitored from 1-1-1996 (n=800,000) 
Exclude subjects who had inconsistent data (n=37,247) 
Diabetes free in 1996-2007 (n=723,451) 50 y, Diabetes patients a (n=39,302) 
DM without OAAs b (n=12,898) 
Successfully matched-pairs (n=9,810): 
   metformin only (n=1,509) 
   sulfonylurea only (n=2,904) 
   sulfonylurea+metformin (n=5,397) 
Affective disorder-free patients matched by date of diagnosis, 
age, gender, region, level of care and comorbidity index 




No DM diagnosis DM with no OAA 




metformin only (n=1,945) 
sulfonylurea only (n=4,094) 
sulfonylurea+metformin (n=11,103) 
Exclude DM patients on OAAs who were not on 
sulfonylurea or metformin (n=9,262)
Figure 2 Patient selection and index date assignment for Study 2. (A) Flow chart of selection of patients with type 2 diabetes who did not
have affective disorder (AD) for assessment of AD incidence. Subjects aged 50 years or over with a diagnosis of type 2 diabetes recorded more
than once within 1 year or who had used any oral anti-hyperglycemic agent (OAA) for at least 3 months during the period 1996 to 2007,
regardless of insulin usage. (B) Patients with no OAA exposure were eligible to serve in the matching process for the various OAA groups.
Subjects with diabetes on sulfonylureas (SU) and/or metformin (Met) and their matched non-OAA treated counterparts had the same treatment
initiation dates (that is, index dates) for follow-up of AD.
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10,000 person-years when men and women were consid-
ered together, and the findings were similar for both
genders (Table 2).
The HRs for sulfonylurea and/or metformin therapy
were compared with the subjects with T2DM but not
on OAAs as the referent group (Table 3). Sulfonylurea
or metformin alone had no significant effect on AD
risk.; however, the combined treatment resulted in an
evident reduction in AD risk of 60% (HR = 0.40; 95% CI
0.32 to 0.50). The findings were similar (HR = 0.42; 95%
CI 0.33 to 0.53) after adjustment for monthly income
and insulin usage. To eliminate any effect of insulin in
combination with OAAs, a sub-analysis excluded all
insulin users; the findings remained unchanged (data
 
               






Figure 3 Relative risks for incident affective disorders by diabetic status and treatment. Hazard ratios (HR) for incident affective disorders
(ADs) by diabetic status without or with oral anti-diabetic agents (OAAs) regardless of insulin usage (using diabetes-free subjects as the
comparison group). We matched AD-free subjects with diabetes aged 20 years or over without or with medication with those who were
diabetes-free, by year and month of birth and gender. Adjustments were made for monthly income (0, 1 to 15,000, 15,000 to 21000, >21000
New Taiwan Dollars (NTD)).







Figure 4 Prevalence (per 1,000) of diabetes and affective disorders in the year 2000. Prevalence was stratified by age group.
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not shown). The order of introduction of the drugs or
whether they were introduced together or separately,
did not alter the significance of this finding either. Simi-
lar results were evident with both unipolar and bipolar
AD, although more so with bipolar AD.
Although subjects were matched for CCI to minimize
any effect on incident AD of underlying or latent disease
at the time of diabetes treatment initiation, the inci-
dences for the first 3 years were progressively excluded
(Figure 5). The HRs for combined sulfonylurea and met-
formin remained significant into the third year for all
incident AD, at 0.67 (0.48 to 0.93). The findings are
similar for both bipolar and unipolar AD, but there was
a trend toward a greater reduction in bipolar AD.
Discussion
Affective disorder and diabetes in Taiwan
In this study, we found that for Taiwanese subjects with
T2DM aged 50 years or over, having no oral anti-hyper-
glycemic therapy is a risk factor for AD, with an overall
increase in risk of 2.62-fold during the period 1996 to
2007. One reason our findings are not negative [11], unlike
those of other studies [12-15], may be that they were not
masked by therapeutic interventions for diabetes that we
have previously found to reduce the risks of dementia [23]
and Parkinson’s disease [24]. Another is that in Taiwan, as
elsewhere, the burden of diabetes in an ageing population
is increasing [17], and thus the phenomenon is more
recognizable. However, in some community-based ageing
populations such as that of Australia, older people do not
necessarily show an increased prevalence of depression
[32]. It is possible that diabetes might play a greater role in
the development of depression or AD in communities in
which its prevalence increases to a greater extent in later
life. Gender did not seem to influence the status of dia-
betes as a risk factor for AD, whether unipolar or bipolar.
This does not diminish the importance of gender differ-
ences in risk for depression or AD that have been recog-
nized for other factors [32], or of the pathogenetic and
clinical differences between the major types of AD, but it
Table 1 Demographics for affective disorder (AD)-free patients with diabetes (DM) using oral anti-hyperglycemic
agents (OAAs) and their matched counterparts without OAA
Study 1 Study 2










Age, mean ± SD years
For matched pair 56.0 ± 15.2 57.5 ± 12.3 67.7 ± 9.1 67.7 ± 9.1 65.7 ± 8.9
At DM diagnosis, 56.0 ± 15.2 57.5 ± 12.3 67.5 ± 8.7 67.5 ± 8.7 65.3 ± 8.2
Age groups, years
<50 35.8 28.6
50 to 54 11.9 13.8 6.0 6.8 10.3
55 to 59 11.2 13.9 16.7 16.6 20.2
60 to 64 10.1 13.9 19.3 17.7 20.4
65 to 69 10.4 12.9 18.8 19.4 19.0
≥70 20.6 16.3 39.2 39.6 30.1
Female gender 52.3 48.3 54.5 50.8 52.5
Locality
North 46.5 42.2 54.2 41.8 45.9
Central 22.3 22.8 18.2 20.8 21.4
South 28.3 31.4 26.1 36.2 31.6
East 2.35 2.94 1.5 1.1 1.1
Offshore 0.66 0.66 0 0.10 0.11
Level of health service
Primary 26.7 28.3 26.5 32.2 30.5
Secondary 53.0 47.1 50.6 49.5 51.5
Tertiary 20.3 24.6 22.9 18.3 18.0
Insulin user 0.0 12.3 4.57 3.13 5.78
CCI, mean ± SD 1.4 ± 1.8 1.6 ± 2.1 1.6 ± 2.2
aIn total, there were 9,810 patients with DM who were free of affective disorder (AD) and were on oral anti-diabetic agents (OAA), and who could be matched for
age, gender, locality, health service, Charlson Comorbidity Index and DM diagnosis date, with those who were free of AD and who were not on OAA. Where
necessary, a patient in the comparison group was used more than once. Thus, there were 9,810 matched pairs. All values are percentages unless indicated.
bPatients diagnosed with DM and treated with metformin,(Met) who had never used insulin during the period 1996 to 2007.
cPatients diagnosed with DM and treated with sulfonylureas (SUs) who had never used insulin during the period 1996 to 2007.
dPatients diagnosed with DM and treated with both Met and SUs, who had never used insulin during the period 1996 to 2007.
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does emphasize the possible commonalities through the
diabetes linkage and raises questions about which of these
might be relevant in prevention and management.
There has been no study to date of T2DM and AD on
East Asian populations, where marked increases in
T2DM prevalence have occurred in recent years, and
where almost half of the world’s population is exposed
to diabetes, and consequently to a potential threat to
mental health. Our study makes a contribution to the
relevance of diabetes as a risk factor for AD in East
Asian populations, as Taiwan has a dominantly Chinese
ethnic population and is therefore an example of a large
under-studied group.
Preventive or therapeutic benefit of oral anti-
hyperglycemic agents for affective disorder
The available studies have not considered diabetes phar-
macotherapy in relation to the effect of diabetes on the
risk for depression or AD, which may have led to lower
estimates of the possible reduction in risk of AD by dia-
betes therapy. In the meta-analysis on Europeans and
North Americans carried out by Nouwen et al. [12], the
increased risk for depression was 24% and in the study
by Nefs et al. [14], it was 14%; given our findings, these
were probably underestimates. We found the increased
risk for incident AD in subjects with T2DM untreated
by OAA to be 2.6-fold (both unipolar and bipolar AD
HRs were similar, at 2.81 and 2.31, respectively), which
suggests that the available studies have grossly underes-
timated the potential effect of diabetes in this area of
mental health.
The combination of sulfonylurea and metformin signif-
icantly reduced both incidence and relative risk for AD in
T2DM, irrespective of gender; there was no such change
evident for sulfonylurea or metformin alone (Table 2,
Table 3). It also did not matter in which order sulfony-
lurea or metformin were started. For any particular inter-
vention, patients were extensively matched with their
reference non-OAA subject, using counterparts with the
same date of diabetes diagnosis, within the same calendar
year. This reduced the possibility that a change in
accepted diabetes management might have accounted for
the observed effects, whether in men or women. Bias,
especially from time, was minimized, and thus made this
cohort study more similar to a clinical trial [29,30]. Dif-
ferences in referent subjects between treatment cate-
gories were addressed by matching for matters such as
accessibility to care (by locality), level of care (by primary
to tertiary or medical center) and associated health status
(CCI) (Table 3).
Despite adjustment for co-morbidities and the exclusion
of incident AD for up to 3 years after introduction of
OAA therapy, the combination of sulfonylurea and met-
formin was still associated with HRs of less than 1.00 com-
pared with no OAA therapy. This applied to both unipolar
and, to a greater extent, bipolar AD. Thus, although differ-
ences between these two forms of AD are well documen-
ted and with agreed therapies, our findings raise the
possibility that there are some common underlying patho-
genetic factors, perhaps related to neurodegeneration.
The findings for the sulfonylurea/metformin combina-
tion rather than either alone would be consistent with
synergistic or complimentary mechanisms of action of the
two agents. Because advanced glycation end-products are
found in the central nervous system (CNS), specifically in
microglia [33], these two OAAs together might act via a
more pronounced anti-hyperglycemic effect. Such an
effect might be combined with specific AD-reduction




ID (95% CI)c Cases/total study
group, n





42/5619 74.7 (52.2 to
97.3)
11/2599 42.3 (17.4 to
67.3)
31/3019 102 (66.7 to
138)
Met only 43/5627 76.4 (53.7 to
99.2)
18/2637 68.2 (36.8 to
99.7)




140/14503 96.5 (80.6 to
112)
52/7101 73.2 (53.4 to
93.1)
88/7402 118 (94.2 to
143)
SUs only 145/13370 108 (90.9 to
126)
59/6581 89.6 (66.9 to
112)




282/30957 91.1 (80.5 to
101)d
100/14064 71.1 (57.2 to
85.0)e
182/16893 107 (92.2 to
123)f
SUs + Met 127/32236 39.4 (32.6 to
46.2)d
45/14791 30.4 (21.5 to
39.3)e
82/17444 47.0 (36.9 to
57.2)f
aAD diagnoses include ICD-9-CM (296) and the equivalent Taiwanese A-code (A212).
aMet, metformin; OAAs: oral anti-diabetic agents; SUs, sulfonylureas.
cID (95% CI): incidence density per 10,000 person-years (95% confidence interval).
d-fThe same superscript vertically indicates that there is a significant difference between the two groups.
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Table 3 Hazard ratios (HRs) and 95% confidence intervals (CIs) for affective disorders (ADs) by date of diabetes diagnosis and diabetes mellitus (DM)
treatment.a,b
ADsc Unipolard Bipolare
Descriptor Cases/total study group, n HR (95% CI) HR (95% CI)f Cases/total study group, n HR (95% CI)f Cases/total study group, n HR (95% CI)f
DM without OAA 42/1509 Ref. Ref. 25/1509 Ref. 17/1509 Ref.
Metformin only 43/1509 0.92 1.00 29/1509 1.28 14/1509 0.61
(0.59 to 1.45) (0.61 to 1.64) (0.68 to 2.40) (0.22 to 1.65)
DM without OAA 140/2904 Ref. Ref. 96/2904 Ref. 44/20904 Ref.
Sulfonylureas only 145/2904 1.08 1.13 97/2904 1.14 48/2904 1.10
(0.84 to 1.38) (0.87 to 1.47) (0.83 to 1.56) (0.68 to 1.78)
DM without OAA 282/5397 Ref. Ref. 189/5397 Ref. 93/5397 Ref.
Sulfonylureas+ Metformin 127/5397 0.40 0.42 83/5397 0.44 44/5397 0.38
(0.32 to 0.50)i (0.33 to 0.53)i (0.33 to 0.60)i (0.25 to 0.58)i
DM without OAA 157/2843 Ref. Ref. 109/2843 Ref. 48/2843 Ref.
SU+Met (SU first) 60/2843 0.32 0.33 36/2843 0.32 24/2843 0.37
(0.23 to 0.44)i (0.23 to 0.47)i (0.21 to 0.50)i (0.20 to 0.68)i
DM without OAA 33/968 Ref. Ref. 18/968 Ref. 15/968 Ref.
SU+Met (Met first) 19/968 0.53 0.45 10/968 0.45 9/968 0.50
(0.29 to 0.98)g (0.23 to 0.89)g (0.17 to 1.17) (0.18 to 1.36)
DM without OAA 92/1586 Ref. Ref. 62/1586 Ref. 30/1586 Ref.
SU+Met (the same time) 48/1586 0.50 0.54 37/1586 0.65 11/1586 0.32
(0.35 to 0.72)i (0.36 to 0.82)i (0.40 to 1.04) (0.14 to 0.75)h
aSubjects were matched by date of diagnosis (within the same calendar year), age group (50 to 54, 55 to 59, 60 to 64, 65 to 69, ≥70 uears), locality, level of care, and Carlson Comorbidity Index.
bOAAs: oral anti-diabetic agents; SU: sulfonylureas; Met: metformin; Ref, reference
cInternational Classification of Diseases(ICD) code 296.
dICD: 296.2, 296.3,
eICD: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 296.9
fAdjusted for monthly income (0, 1-15,000, 15,000-21000, >21000 NTD) and insulin usage (yes, no).



















actions of the drugs. As mentioned above, metformin
might operate through mechanisms that are protective
against neurodegeneration, if this is a shared pathogenesis
with AD. When diabetes affects the CNS, AD might share
underlying mechanisms with neurodegenerative diseases
such as dementia and Parkinsonism [23,24]. We previously
reported that T2DM also increases the risk of dementia by
2.6-fold, and that the combination of sulfonylureas and
metformin was able to decrease the risk of dementia in
diabetes within 12-years [23], with similar findings in PD
[24]. These collective findings strengthen the case for a
linkage between brain diabetes, neurodegenerative disease,
and AD, a conjunction already in evidence from various
pathophysiological studies [33,34]. Chen et al.. found that
metformin might increase the biogenesis of amyloid pep-
tides in Alzheimer’s disease, which could be relevant if
there is a shared pathogenesis with depression, so our
population-wide study supports this idea [35].
The definition of OAA usage in our models was a pre-
scription for at least 3 months. Minimal doses for metfor-
min were equivalent to about 500 mg per day and, for
sulfonylureas, one standard tablet or capsule per day.
These therapeutic regimens are feasible for most people
with T2DM, and may largely remove the risk of AD
posed by diabetes within 12 years of starting treatment.
Owing to the limited number of subjects with T2DM on
insulin therapy in this study, we did not treat them sepa-
rately. Controlling for or exclusion of insulin usage in the
models made no difference to our findings about OAAs
and AD.
Issues in the diagnosis of affective disorder in diabetes
The Taiwanese NHI claim data rely on the medical ser-
vice utilization of patients and on medical diagnoses.
Underdiagnosis of AD and DM is likely if the reach of a





















Figure 5 Risk of affective disorder (AD) with sequential exclusion of its incidence for up to 3 years. Hazard ratios (HRs) for incident ADs
by date of diabetes diagnosis and type of diabetes treatment, with sequential exclusion of its incidence for up to 3 years. HRs with 95%
confidence intervals (CIs) are shown. In the models used, subjects were matched by date of diagnosis (within the same calendar year), age
group (50 to 54, 55 to 59, 60 to 64, 65 to 69, and ≥70 years), locality, level of care, and comorbidity index, and were adjusted for monthly
income (0, 1 to 15,000, 15,000 to 21000, >21000 New Taiwan Dollars (NTD)). The upper CIs are, respectively, 17.6, 28.8, and 28.8, but bar lengths
have been omitted in the figure because of scale.
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98% of the population in Taiwan and, with the use of
our matching protocol for accessibility (that is, region,
level of service, and income), underdiagnosis should
have been minimized. For social reasons, AD may be
under-reported, but this is less likely with diabetes
because of frequent and more intensive contact with the
health system. Nevertheless, clinicians may have a ten-
dency to simplify the diagnostic list when patients have
multisystem diseases such as diabetes, in favor of the
‘less pressing’ diagnoses, which might therefore mean
less recording of AD.
We have no information about the diagnosis of either
diabetes or AD before 1996, when the NHI started, but
it is unlikely that the presence of either of these would
not have been recorded by a medical practitioner at
some subsequent consultation. However, because the
diagnosis of bipolar AD depends on at least two visits,
such conditions may have been under-diagnosed as a
consequence. Thus, there are several factors which may
affect AD diagnosis rates, and thus their net effect on
the differentials with regard to antecedent diabetes
remains unclear.
A valuable insight into the validity of these diagnostic
rates comes from the relevance of diagnostic methods,
whether questionnaire or psychiatric diagnosis [12]. Dif-
ferences in estimates have been found to be dependent
on year of publication of the report, but also to be prob-
ably increasing with time. Thus, there are questions
about how contemporary our work, using 1996 datasets,
might be regarded, because, as an NHI system require-
ment, we used ICD-9 for the diagnosis of AD rather
then ICD-10 or DSM-IV. The ICD-9 codes used in the
present study were 296.0 to 296.9 and its Taiwanese
coding counterpart was A212 (before year 2000); never-
theless, these do cover ICD-10 codes F30 to F33 and
F38 to F39, and thus, our study should be replicable.
We recognize that using the DSM-IV would have been a
more useful approach to the diagnosis of depression and,
more particularly, mood or AD, because it includes clinical
symptoms and other axes that would have provided more
analytical scope. However, it is reassuring that there can
be some convergence of the risk assessment for diabetes
on depression or AD, even using different methods [12].
At the same time, our large and representative population-
based study has allowed a more detailed understanding of
the association of diabetes with different mood disorders
than would otherwise have been possible.
Limitations
In our study of AD, we considered both its unipolar and
bipolar forms, but not dysthymic disorders, thus our
findings are not applicable to all forms of depression.
With regard to diabetes as a risk factor for AD, there
seems to be no gender difference. Nor did we find any
apparent difference between unipolar and bipolar AD,
although sample size may have been limiting. Because
incident AD was progressively excluded in the models,
sample size diminished. Therefore, we may not have
been able to discern more substantial and longer-term
differences between unipolar and bipolar AD insofar as
OAA effects are concerned.
T2DM and depression or AD seem to be at least bidir-
ectional, if not mutually reinforcing [10,36]. This process
may begin at an early stage in the evolution of diabetes
from pre-diabetic states and in the early stages of depres-
sive illness. We did not study pre-diabetes subjects, but
we did track individuals through what will have been that
phase, from being diabetes-free in the 1996 to 2007
cohort. From other evidence [10,36], we cannot fully
exclude effects on depression-induced diabetes, which
may have, in turn, increased AD incidence.
The study cohort is an administrative sample for which
measures of diabetes severity are not available. Therefore,
we do not have dose-response data for the studied OAAs
and glycemic control. However, we can say that this parti-
cular OAA combination changes the risk for AD in
T2DM, what the minimal dosages are likely to be for pro-
tection against AD, and how long it might take for these
effects to be evident, as these informed the method we
used to establish exposures. Matching for CCI, which
partly represents diabetes-related complications and its
severity, make it more likely that we observed a genuine
OAA effect rather than one simply of glycemic control,
although the latter is still possible.
Although ours is not an intervention study, we found at
least one OAA combination which could enhance risk
reduction for AD. This is unlikely to be a surrogate for
other potential determinants of risk like body mass index.
Moreover, were this combination of sulfonylurea and met-
formin to operate to reduce AD risk through a possible
surrogate like body mass index, it might well be that these
OAA act in directions opposite from each other, given
their known opposite effects on body mass index. Unfortu-
nately, these covariates are unavailable.
Implications
It is difficult to say how early or late in the course of dia-
betes it may be possible for OAAs to reduce the risk of
AD, but if the association is causal and has an underlying
pathogenesis shared with neurodegeneration, then the
responsive period is likely to be earlier rather than later.
Therefore, the early recognition of those at risk for dia-
betes may allow reduction in the burden of depression. It
is now recommended that metformin should form part of
the therapeutic management of T2DM as early in its
course as possible because of the superior cardiovascular
and all-cause mortality outcomes with this drug compared
with other OAAs [37]. We consider that a broader view of
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diabetes comorbidity and its management will stimulate
interest in changing diabetes therapeutics, with the pro-
spects of a significant reduction in the burden of disease
seen with the tandem of diabetes and AD.
Conclusions
In a large cohort representative of the Taiwanese popula-
tion, followed for up to 12 years, T2DM increased the
risk of AD 2.6-fold. However, the HR for AD for patients
taking combined sulfonylurea and metformin remained
significantly decreased into the third year for all incident
AD at 0.67 (0.48 to 0.93), and this was evident for both
bipolar and unipolar AD. As the global burden of diabetes
increases, these findings may be relevant to the reduction
of its mental-health complications.
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